Express Scripts staking out million dollar gene therapies

Reuters

16 August 2018 - Express Scripts built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Express Scripts is in talks with biotechnology companies BioMarin, Spark Therapeutics and Bluebird Bio to have its specialty pharmaceutical business exclusively distribute their new gene therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

BioMarin, Spark and Bluebird confirmed to Reuters that they were speaking to a payers - a group generally defined as pharmacy benefit managers, health plans and government agencies.

Read Reuters article


Michael Wonder

Posted by:

Michael Wonder